In Search of the Optimal Depth for Self-Expandable Valves

Despite the use of the different imaging approaches to calculating implantation depth, optimal depth is reached only 30% of the time. Multiple imaging does not offer a uniform perspective and therefore influence reporting. 

prótesis autoexpandibles

Basically, we do not have a clear idea of what constitutes optimal depth on a case by case basis and, what is worse, even though we knew the exact point, there is little chance of reaching accurate implantation depth. 

Clinical and hemodynamic outcomes of 258 patients undergoing TAVR with third generation self-expandable valves were analyzed as to their approach to optimal depth calculation: arithmetic mean, the arithmetic mean of the measured distances from the noncoronary cusp and the left coronary cusp to the distal prosthesis end; noncoronary cusp distance, the distance from the noncoronary cusp to the distal prosthesis end, and the deepest edge of the distal prosthesis end, among others.

Regardless the approach, exact implantation depth was achieved in less than 30% of cases. 


Read also: Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?


The deepest edge method is the most precise to differentiate a few relevant outcome parameters, such as the need for permanent pacemaker implantation. 

The hemodynamic outcomes were not affected, regardless success. 

Conclusion

Optimal implantation depth could only be achieved in less than 30% of patients, regardless the approach used to calculate it. In addition, the different approaches do not offer a uniform perspective to calculate the exact implantation depth. 

 

Original title: Navigating the “Optimal Implantation Depth” With a Self-Expandable TAVR Device in Daily Clinical Practice.

Reference: Kerstin Piayda et al. J Am Coll Cardiol Intv 2020, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....